biostudies-literatureUnknown14Sanz-Munoz I<h4>Introduction</h4>The third dose of the COVID-19 vaccine is especially necessary in people over 65 years of age due to their lower immune response.<h4>Methods</h4>We designed a multicentre, prospective observational study including 98 people ≤65 years old who lived in two nursing homes in Valladolid, Spain. One of the groups had previous experience with SARS-CoV-2 (n=68;69.4%) and the other was naïve (n=30;30.6%). We evaluated the response to the three doses of the Comirnaty vaccine and the dynamics of antibodies during 5 consecutive serum samplings: 2 after the first two doses of vaccination, one three months after the first dose, another at 6 months and the last one month after the third dose. IgG antibodies against SARS-CoV-2 S1, RBD and N antigens were analysed.<h4>Results</h4>Both Frontiers in immunology1128302https://www.ebi.ac.uk/biostudies/studies/S-EPMC9992205biostudies-literatureEvolution of antibody profiles against SARS-CoV-2 in experienced and naive vaccinated elderly people.PMC9992205de Lejarazu-Leonardo ROCastrodeza-Sanz JSanchez-de Prada LRojo-Rello SHernan-Garcia CGonzalez MDLopez-Mongil REiros JMFernandez-Espinilla VSanchez-Martinez JSanz-Munoz IPerez-SanJose DfalseEvolution of antibody profiles against SARS-CoV-2 in experienced and naive vaccinated elderly people.<h4>Introduction</h4>The third dose of the COVID-19 vaccine is especially necessary in people over 65 years of age due to their lower immune response.<h4>Methods</h4>We designed a multicentre, prospective observational study including 98 people ≤65 years old who lived in two nursing homes in Valladolid, Spain. One of the groups had previous experience with SARS-CoV-2 (n=68;69.4%) and the other was naïve (n=30;30.6%). We evaluated the response to the three doses of the Comirnaty vaccine and the dynamics of antibodies during 5 consecutive serum samplings: 2 after the first two doses of vaccination, one three months after the first dose, another at 6 months and the last one month after the third dose. IgG antibodies against SARS-CoV-2 S1, RBD and N antigens were analysed.<h4>Results</h4>Both 2023-01-01T00:00:00Z20232025-04-04T18:50:48.858Z2025-04-04T18:50:48.858ZS-EPMC99922053691167310.3389/fimmu.2023.1128302